Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

RNA-based FLT3 -ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML

Blood (2018) 131 (22): 2485–2489.

https://doi.org/10.1182/blood-2017-12-819508

Published: 2018

Includes: Supplemental data

Journal Articles

Prospective Molecular MRD Detection By NGS: A Powerful Independent Predictor for Relapse and Survival in Adults with Newly Diagnosed AML

Blood (2017) 130 (Supplement 1): LBA-5.

https://doi.org/10.1182/blood.V130.Suppl_1.LBA-5.LBA-5

Published: 2017

Journal Articles

The Relevance of Stem Cell Load at Diagnosis for the Development of Relapse in Pediatric Acute Myeloid Leukemia

Dirkje W. Hanekamp, Barbara Denys, Gertjan J.L. Kaspers, MD PhD, Jeroen G. te Marvelde, Gerrit Jan Schuurhuis, PhD, Valerie De Haas, MD PhD, Barbara De Moerloose, MD PhD, Eveline S. de Bont, Anja de Jong, Jan Philippé, MD PhD, Jacqueline Cloos, PhD, Vincent H.J. van der Velden, PhD

Blood (2015) 126 (23): 2584.

https://doi.org/10.1182/blood.V126.23.2584.2584

Published: 2015

Journal Articles

The Antibody-Drug Conjugate (ADC) IMGN779 Is Highly Active in Vitro and in Vivo Against Acute Myeloid Leukemia (AML) with FLT3-ITD Mutations

Kathleen R Whiteman, MS, Paul Noordhuis, PhD, Russell Walker, MS, Krystal Watkins, MS, Yelena Kovtun, PhD, Lauren Harvey, BS, Alan Wilhelm, BS, Holly Johnson, BS, Gerrit Jan Schuurhuis, PhD, Gert J Ossenkoppele, MD PhD, Robert J. Lutz, PhD

Blood (2014) 124 (21): 2321.

https://doi.org/10.1182/blood.V124.21.2321.2321

Published: 2014

Journal Articles

Microrna-551b Is Preferentially Expressed In Hematopoietic Stem and Multipotent Progenitor Cells and High Expression In Acute Myeloid Leukemia Is An Independent Prognostic Factor For Relapse and Poor Survival

David C. de Leeuw, MD, Fedor Denkers, Peter J. Valk, PhD, Gerrit Jan Schuurhuis, PhD, Gert J. Ossenkoppele, MD PhD, Linda Smit, PhD

Blood (2013) 122 (21): 1322.

https://doi.org/10.1182/blood.V122.21.1322.1322

Published: 2013

Journal Articles

Leukemic Stem Cell Quantification Is Of Prognostic Value In Newly Diagnosed Patients In Chronic Phase Chronic Myeloid Leukemia (CML-CP) Receiving Nilotinib Therapy: Results From The ENEST1st Stem Cell Substudy

Noortje Thielen, MD, Johan Richter, MD, PhD, Gisela Barbany, MD PhD, Thoas Fioretos, MD PhD, Frank Giles, MD MB, Bjorn T Gjertsen, MD PhD, Andreas Hochhaus, MD, Gert J. Ossenkoppele, MD PhD, Kimmo Porkka, MD, PhD, Gerrit Jan Schuurhuis, PhD, Sieghart Sopper, PhD, Leif Stenke, MD, PhD, Sara Thunberg, PhD, Dominik Wolf, MD, Jeroen Janssen, MD PhD, Satu Mustjoki, MD, PhD

Blood (2013) 122 (21): 649.

https://doi.org/10.1182/blood.V122.21.649.649

Published: 2013

Journal Articles

MRD in AML: time for redefinition of CR?

Gert Ossenkoppele, Gerrit Jan Schuurhuis

Blood (2013) 121 (12): 2166–2168.

https://doi.org/10.1182/blood-2013-01-480590

Published: 2013

Journal Articles

Frequency and Prognostic Relevance of Gene Mutations in Pediatric AML Patients At First Relapse.

Costa Bachas, MSc, Gerrit Jan Schuurhuis, PhD, Dirk Reinhardt, MD, Ursula Creutzig, MD, PhD, Zinia J. Kwidama, BSc, C. Michel Zwaan, MD, PhD, Marry M. van den Heuvel-Eibrink, Evelina S De Bont, MD, PhD, Sara Elitzur, MD, Carmelo Rizzari, MD, PhD, Valérie de Haas, MD, PhD, Martin Zimmermann, Jacqueline Cloos, PhD, Gertjan J.L. Kaspers, MD, PhD

Blood (2012) 120 (21): 2480.

https://doi.org/10.1182/blood.V120.21.2480.2480

Published: 2012

Journal Articles

Harnessing Gene Expression Profiles for the Identification of Drug Resistance Genes in Pediatric AML

Costa Bachas, MSc, Gerrit Jan Schuurhuis, PhD, C. Michel Zwaan, MD, PhD, Marry M. van den Heuvel-Eibrink, Monique L. Den Boer, PhD, Zinia J. Kwidama, BSc, Evelina S. De Bont, MD, PhD, Dirk Reinhardt, MD, Ursula Creutzig, MD, PhD, Valérie de Haas, MD, PhD, Yehuda Assaraf, PhD, Gertjan J.L. Kaspers, MD, PhD, Jacqueline Cloos, PhD

Blood (2012) 120 (21): 283.

https://doi.org/10.1182/blood.V120.21.283.283

Published: 2012

Journal Articles

Relapsed AML Patients with Mutational Shifts Harbor An Oligoclonal Primitive Cell Compartment at Presentation; Evidence for Clonal Selection towards Relapse

Costa Bachas, Gerrit Jan Schuurhuis, PhD, Zinia J. Kwidama, Angèle Kelder, Alexander N. Snel, Gertjan J. Kaspers, MD, PhD, Jacqueline Cloos, PhD

Blood (2010) 116 (21): 751.

https://doi.org/10.1182/blood.V116.21.751.751

Published: 2010

Journal Articles

High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine

Costa Bachas, Gerrit Jan Schuurhuis, Iris H. I. M. Hollink, Zinia J. Kwidama, Bianca F. Goemans, C. Michel Zwaan, Marry M. van den Heuvel-Eibrink, Eveline S. J. M. de Bont, Dirk Reinhardt, Ursula Creutzig, Valerie de Haas, Yehuda G. Assaraf, Gertjan J. L. Kaspers, Jacqueline Cloos

Blood (2010) 116 (15): 2752–2758.

https://doi.org/10.1182/blood-2010-03-276519

Published: 2010

Includes: Supplemental data

Journal Articles

Frequent Instability of Type I and II Aberrations Between Diagnosis and Relapse Observed in Pediatric Aml; Implications for Targeted Therapy and MRD Detection.

Costa Bachas, MSc, Gerrit-Jan Schuurhuis, Iris H.I.M. Hollink, MD, Bianca F. Goemans, MD, PhD, Dirk Reinhardt, MD, PhD, Christian M Zwaan, MD, PhD, Marry M. van den Heuvel, MD, PhD, Eveline S.J.M de Bont, Elisabeth R. Van Wering, Gertjan Kaspers, MD, PhD, Jacqueline Cloos, PhD

Blood (2009) 114 (22): 1624.

https://doi.org/10.1182/blood.V114.22.1624.1624

Published: 2009

Journal Articles

A New Flowcytometry-Based Method to Discriminate Malignant From Normal Stem Cells in CML.

Jeroen J.W.M. Janssen, MD, Wendy Deenik, Karlijn G.M. Smolders, Monique Terwijn, Angele Kelder, J. J. Cornelissen, Gerrit-Jan Schuurhuis, Gert J. Ossenkoppele

Blood (2009) 114 (22): 3245.

https://doi.org/10.1182/blood.V114.22.3245.3245

Published: 2009

Journal Articles

Aberrant Phenotype of Stem Cells as Assessed by Flow Cytometry Discriminates Between Low and High Risk Myelodysplastic Syndromes and Might Be Instrumental in Predicting Leukemic Evolution.

Theresia M Westers, PhD, Canan Alhan, MD, Monique Terwijn, Claudia Cali, Yvonne FCM van der Veeken, Gerrit Jan Schuurhuis, PhD, Gert J Ossenkoppele, MD, PhD, Arjan A van de Loosdrecht, MD, PhD

Blood (2009) 114 (22): 3798.

https://doi.org/10.1182/blood.V114.22.3798.3798

Published: 2009

Journal Articles

Leukemic Stem Cell Assessment in Remission Bone Marrow of Acute Myeloid Leukemia Patients Is a New Prognostic Parameter.

Monique Terwijn, Angèle Kelder, Arjo P Rutten, Alexander N Snel, Willemijn Scholten, Sonja Zweegman, MD, PhD, Gert Ossenkoppele, MD, PhD, Gerrit Jan Schuurhuis, PhD

Blood (2009) 114 (22): 399.

https://doi.org/10.1182/blood.V114.22.399.399

Published: 2009

Journal Articles

Expression of C-Type Lectin-Like Molecule-1 (CLL-1) on Stem Cells Might Discriminate De Novo Acute Myeloid Leukemia from Acute Myeloid Leukemia Originating from Myelodysplastic Syndromes

Theresia M Westers, PhD, Monique Terwijn, MSc, Canan Alhan, MD, Yvonne FCM van der Veeken, Claudia Cali, Angele Kelder, Anna van Rhenen, MD, PhD, Gerrit Jan Schuurhuis, PhD, Gert J Ossenkoppele, MD, PhD, Arjan A van de Loosdrecht, MD, PhD

Blood (2008) 112 (11): 2697.

https://doi.org/10.1182/blood.V112.11.2697.2697

Published: 2008

Journal Articles

High Leukemic Stem Cell Frequency in Remission Bone Marrow Predicts Poor Outcome in Acute Myeloid Leukemia

Terwi J Monique, MSc, Angèle Kelder, Arjo P Rutten, Gert J Ossenkoppele, MD, PhD, Sonja Zweegman, MD, PhD, Gerrit Jan Schuurhuis, PhD

Blood (2008) 112 (11): 2537.

https://doi.org/10.1182/blood.V112.11.2537.2537

Published: 2008

Journal Articles

Specific Detection of Aberrant and Normal Stem Cells in Acute Myeloid Leukemia Patients Opens the Way for Defining Highly Specific Targets for Stem Cell Therapy.

J Monique Terwi, MSc, Angèle Kelder, Arjo P Rutten, Sonja Zweegman, MD, PhD, Gert J Ossenkoppele, MD, PhD, Gerrit Jan Schuurhuis, PhD

Blood (2008) 112 (11): 1353.

https://doi.org/10.1182/blood.V112.11.1353.1353

Published: 2008

Journal Articles

The novel AML stem cell–associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells

Anna van Rhenen, Guus A. M. S. van Dongen, Angèle Kelder, Elwin J. Rombouts, Nicole Feller, Bijan Moshaver, Marijke Stigter-van Walsum, Sonja Zweegman, Gert J. Ossenkoppele, Gerrit Jan Schuurhuis

Blood (2007) 110 (7): 2659–2666.

https://doi.org/10.1182/blood-2007-03-083048

Published: 2007

Journal Articles

Methylation of ESR1 and Tumour Suppressor Genes Together Constitute an Independent Outcome Predictor in Acute Myeloid Leukemia.

Corine J. Hess, MD, Johannes Berkhof, PhD, Fedor Denkers, Gert J. Ossenkoppele, MD/PhD, Gerrit Jan Schuurhuis, PhD, Quinten Waisfisz, PhD

Blood (2006) 108 (11): 803.

https://doi.org/10.1182/blood.V108.11.803.803

Published: 2006

NARROW

RNA-based FLT3 -ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML

Prospective Molecular MRD Detection By NGS: A Powerful Independent Predictor for Relapse and Survival in Adults with Newly Diagnosed AML

The Relevance of Stem Cell Load at Diagnosis for the Development of Relapse in Pediatric Acute Myeloid Leukemia

The Antibody-Drug Conjugate (ADC) IMGN779 Is Highly Active in Vitro and in Vivo Against Acute Myeloid Leukemia (AML) with FLT3-ITD Mutations

Microrna-551b Is Preferentially Expressed In Hematopoietic Stem and Multipotent Progenitor Cells and High Expression In Acute Myeloid Leukemia Is An Independent Prognostic Factor For Relapse and Poor Survival

Leukemic Stem Cell Quantification Is Of Prognostic Value In Newly Diagnosed Patients In Chronic Phase Chronic Myeloid Leukemia (CML-CP) Receiving Nilotinib Therapy: Results From The ENEST1st Stem Cell Substudy

MRD in AML: time for redefinition of CR?

Frequency and Prognostic Relevance of Gene Mutations in Pediatric AML Patients At First Relapse.

Harnessing Gene Expression Profiles for the Identification of Drug Resistance Genes in Pediatric AML

Relapsed AML Patients with Mutational Shifts Harbor An Oligoclonal Primitive Cell Compartment at Presentation; Evidence for Clonal Selection towards Relapse

High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine

Frequent Instability of Type I and II Aberrations Between Diagnosis and Relapse Observed in Pediatric Aml; Implications for Targeted Therapy and MRD Detection.

A New Flowcytometry-Based Method to Discriminate Malignant From Normal Stem Cells in CML.

Aberrant Phenotype of Stem Cells as Assessed by Flow Cytometry Discriminates Between Low and High Risk Myelodysplastic Syndromes and Might Be Instrumental in Predicting Leukemic Evolution.

Leukemic Stem Cell Assessment in Remission Bone Marrow of Acute Myeloid Leukemia Patients Is a New Prognostic Parameter.

Expression of C-Type Lectin-Like Molecule-1 (CLL-1) on Stem Cells Might Discriminate De Novo Acute Myeloid Leukemia from Acute Myeloid Leukemia Originating from Myelodysplastic Syndromes

High Leukemic Stem Cell Frequency in Remission Bone Marrow Predicts Poor Outcome in Acute Myeloid Leukemia

Specific Detection of Aberrant and Normal Stem Cells in Acute Myeloid Leukemia Patients Opens the Way for Defining Highly Specific Targets for Stem Cell Therapy.

The novel AML stem cell–associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells

Methylation of ESR1 and Tumour Suppressor Genes Together Constitute an Independent Outcome Predictor in Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only